IL166040A0 - Compounds useful for the treatment of diseases responsive to antiangiogenetic therapy - Google Patents

Compounds useful for the treatment of diseases responsive to antiangiogenetic therapy

Info

Publication number
IL166040A0
IL166040A0 IL16604003A IL16604003A IL166040A0 IL 166040 A0 IL166040 A0 IL 166040A0 IL 16604003 A IL16604003 A IL 16604003A IL 16604003 A IL16604003 A IL 16604003A IL 166040 A0 IL166040 A0 IL 166040A0
Authority
IL
Israel
Prior art keywords
treatment
compounds useful
diseases responsive
diseases
antiangiogenetic
Prior art date
Application number
IL16604003A
Other languages
English (en)
Original Assignee
Neurosearch As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurosearch As filed Critical Neurosearch As
Publication of IL166040A0 publication Critical patent/IL166040A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Electrotherapy Devices (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Inorganic Compounds Of Heavy Metals (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL16604003A 2002-08-01 2003-07-31 Compounds useful for the treatment of diseases responsive to antiangiogenetic therapy IL166040A0 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DKPA200201165 2002-08-01
DKPA200201839 2002-11-28
DKPA200300371 2003-03-11
PCT/DK2003/000518 WO2004012733A2 (en) 2002-08-01 2003-07-31 Compounds useful for the treatment of diseases responsive to antiangiogenetic therapy

Publications (1)

Publication Number Publication Date
IL166040A0 true IL166040A0 (en) 2006-01-15

Family

ID=31498946

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16604003A IL166040A0 (en) 2002-08-01 2003-07-31 Compounds useful for the treatment of diseases responsive to antiangiogenetic therapy

Country Status (17)

Country Link
US (1) US20060058395A1 (de)
EP (1) EP1526851B1 (de)
JP (1) JP2005537336A (de)
KR (1) KR20050026091A (de)
CN (1) CN1671378A (de)
AT (1) ATE372770T1 (de)
AU (1) AU2003260280A1 (de)
BR (1) BR0312929A (de)
CA (1) CA2493253A1 (de)
DE (1) DE60316297T2 (de)
IL (1) IL166040A0 (de)
IS (1) IS7723A (de)
MX (1) MXPA05001235A (de)
NO (1) NO20051074L (de)
NZ (1) NZ537809A (de)
PL (1) PL375318A1 (de)
WO (1) WO2004012733A2 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1805942B (zh) * 2003-06-17 2010-06-02 神经研究公司 二苯基脲衍生物及其作为氯离子通道阻断剂的用途
US7550499B2 (en) 2004-05-12 2009-06-23 Bristol-Myers Squibb Company Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
MX2007008434A (es) 2005-01-19 2007-07-25 Squibb Bristol Myers Co Derivados de 2-fenoxi-n-(1,3,4-tiadizol-2il)piridin-3-amina y compuestos relacionados como inhibidores del receptor p2y1 para el tratamiento de trastornos tromboembolicos.
EP1853286A2 (de) * 2005-02-08 2007-11-14 BMZ Diagnosis (2004) Ltd. Zusammensetzung zur behandlung von hauterkrankungen
AR056867A1 (es) 2005-06-27 2007-10-31 Bristol Myers Squibb Co Antagonistas heterociclicos n- enlazados del receptor de p2y1 utiles en el tratamiento de condiciones tromboticas. composiciones farmaceuticas.
WO2007002634A1 (en) 2005-06-27 2007-01-04 Bristol-Myers Squibb Company Carbocycle and heterocycle antagonists of p2y1 receptor useful in the treatment of thrombotic conditions
ATE485269T1 (de) 2005-06-27 2010-11-15 Bristol Myers Squibb Co C-verknüpfte zyklische antagonisten des p2y1- rezeptors mit eignung bei der behandlung thrombotischer leiden
WO2007002584A1 (en) 2005-06-27 2007-01-04 Bristol-Myers Squibb Company Linear urea mimics antagonists of p2y1 receptor useful in the treatment of thrombotic conditions
US7960569B2 (en) 2006-10-17 2011-06-14 Bristol-Myers Squibb Company Indole antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
WO2009054878A2 (en) * 2007-09-11 2009-04-30 University Of Florida Research Foundation Compositions and methods for the treatment of neoplasia
WO2016001452A1 (en) * 2014-07-04 2016-01-07 Universität Zürich Compounds, in particular for use in the treatment of a disease or condition for which a bromodomain inhibitor is indicated
ES2770374T3 (es) * 2016-05-17 2020-07-01 Scandion Oncology As Tratamiento combinado de cáncer
WO2020049139A1 (en) * 2018-09-06 2020-03-12 Scandion Oncology A/S Urea derivatives for use in the treatment of subjects with elevated expression and/or activity of srpk1

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11503110A (ja) * 1995-02-17 1999-03-23 スミスクライン・ビーチャム・コーポレイション Il−8受容体拮抗剤
TR199902593T2 (xx) * 1997-04-22 2000-03-21 Neurosearch A/S �kame edilmi� fenil t�revleri, bunlar�n haz�rlanmas� ve kullan�m�.
ATE291011T1 (de) * 1997-12-22 2005-04-15 Bayer Pharmaceuticals Corp Hemmung der raf-kinase unter verwendung von symmetrisch und unsymmetrisch substituierten harnstoffen
EP1514867A3 (de) * 1998-10-22 2005-03-23 NeuroSearch A/S Substituierte Phenylderivate, ihre Herstellung und Verwendung
CO5200760A1 (es) * 1999-06-16 2002-09-27 Smithkline Beecham Corp Antagonistas del receptor de la il-8 ceptor il-8
US6875782B2 (en) * 2002-07-09 2005-04-05 Bristol-Myers Squibb Company Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method

Also Published As

Publication number Publication date
WO2004012733A9 (en) 2005-03-10
IS7723A (is) 2005-03-01
EP1526851B1 (de) 2007-09-12
JP2005537336A (ja) 2005-12-08
DE60316297D1 (de) 2007-10-25
AU2003260280A1 (en) 2004-02-23
WO2004012733A3 (en) 2004-03-18
MXPA05001235A (es) 2005-06-08
ATE372770T1 (de) 2007-09-15
US20060058395A1 (en) 2006-03-16
EP1526851A2 (de) 2005-05-04
NO20051074L (no) 2005-04-29
BR0312929A (pt) 2005-07-12
DE60316297T2 (de) 2008-06-19
NZ537809A (en) 2007-05-31
KR20050026091A (ko) 2005-03-14
WO2004012733A2 (en) 2004-02-12
PL375318A1 (en) 2005-11-28
CN1671378A (zh) 2005-09-21
CA2493253A1 (en) 2004-02-12

Similar Documents

Publication Publication Date Title
AU2003272285A8 (en) Thienopyrrolyl and furanopyrrolyl compounds and their use as histamine h4 receptor ligands
UA83194C2 (ru) Производные пиримидина и их применение как модуляторов св2
MY145077A (en) Pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
PL375318A1 (en) Compounds useful for the treatment of diseases responsive to antiangiogenetic therapy
MY141867A (en) Substituted pyrimidines useful as protein kinase inhibitors
GB0222495D0 (en) Compounds
TW200509892A (en) Novel aminobenzophenone compounds
BE2010C030I2 (de)
AU2002327378A1 (en) Treatment of neuropsychiatric disorders by near-diaphragmatic nerve stimulation
IL147271A0 (en) Compounds that bind her2
MXPA04004064A (es) Derivados heteroaromaticos de carboxamida para el tratramiento de la inflamacion.
ATE381935T1 (de) Verwendung von triacetyluridin zur behandlung von mitochondrialen erkrankungen
IL172942A0 (en) Pyrazoloisoquinoline derivatives as kinase inhibitors
WO2005023815A3 (en) Neuroprotective bicyclic compounds and methods for their use
WO2005014814A3 (en) 5’-and 3’-capped aptamers and uses therefor
DE50305587D1 (en) 2-heteroarylcarbonsäureamide
WO2003039539A3 (de) Verwendung von endothelin-rezeptor-antagonisten zur behandlung von tumorerkrankungen
AU2003260436A1 (en) Pyrimidine compounds
PL376149A1 (en) Piperazine and piperidine derivatives for treatment of neurological diseases
WO2004084809A3 (en) Neuroprotective macrocylic compounds and methods for their use
EP1436279A4 (de) Chemische verbindungen
TW200505435A (en) Treatment of ocular disorders
WO2006004774A3 (en) Laulimalide analogues as therapeutic agents
WO2003064394A8 (de) 5-ring heterozyklen zur verwendung als antiviral mittel
WO2004019959A3 (en) Dna repair enzymes